Focused On-demand Library for Eukaryotic peptide chain release factor GTP-binding subunit ERF3A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P15170

UPID:

ERF3A_HUMAN

Alternative names:

G1 to S phase transition protein 1 homolog

Alternative UPACC:

P15170; J3KQG6; Q96GF2

Background:

Eukaryotic peptide chain release factor GTP-binding subunit ERF3A, also known as GSPT1 or G1 to S phase transition protein 1 homolog, plays a crucial role in translation termination. It forms part of the eRF1-eRF3-GTP ternary complex, which mediates translation termination at stop codons UAA, UAG, and UGA. This protein is essential for delivering ETF1/ERF1 to stop codons, facilitating GTP hydrolysis, and inducing conformational changes for translation termination. Additionally, ERF3A is a component of the SURF complex, involved in nonsense-mediated decay (NMD) and is required for SHFL-mediated translation termination, which inhibits programmed ribosomal frameshifting.

Therapeutic significance:

Understanding the role of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A could open doors to potential therapeutic strategies.